No elevated risk for stroke seen after COVID-19 bivalent vaccine receipt
Mar 20, 2024
No evidence was seen for an increased risk for stroke in one- to 21-day or 22- to 42-day windows compared with a 43- to 90-day window after the vaccine.
Bivalent mRNA-1273.214 elicits better response against omicron
Sep 27, 2022
A booster dose of mRNA-1273.214 elicits more neutralizing antibodies against omicron compared with mRNA-1273, the original Moderna vaccine, with no new safety concerns.
COVID-19 hospitalization rates higher in unvaccinated during omicron
Sep 14, 2022
Hospitalization rates were 2.5 times higher for vaccinated patients without booster versus those with a booster.
Single dose of RSV vaccine prevents acute respiratory infection in seniors
Feb 17, 2023
High vaccine efficacy was seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions.
RSVpreF safe, effective for preventing respiratory syncytial virus illness in seniors
Apr 10, 2023
The findings seen in phase 3 trial of adults aged 60 years and older receiving a single intramuscular injection of RSVpreF vaccine.
FDA panel backs Pfizer RSV vaccine for older Americans
Mar 01, 2023
Pfizer has reported that its vaccine would reduce risk from RSV by as much as 86%.